Expanding the definition of hypertension to incorporate global cardiovascular risk
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Recent epidemiologic analyses have changed the way that hypertension is viewed. Cardiovascular risk has been found to be elevated at levels of blood pressure previously believed to be normal and not imparting additional risk. Furthermore, the approach to hypertension has been shifted from viewing and treating it in isolation to a more comprehensive approach that incorporates a focus on global cardiovascular risk and the risk factors commonly associated with having an elevated blood pressure. However, control rates not only for hypertension but also for associated risk factors, such as hyperlipidemia and diabetes, remain abysmal, providing an even greater challenge to providers of care. To change this alarming trend, physicians must become aggressive in using the available armamentarium of lifestyle modifications and drugs in treating hypertension and other risk factors that increase the burden of atherosclerosis.
- Cheung BM, Ong KL, Man YB, et al.: Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens (Greenwich) 2006, 8:93–98. CrossRef
- Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572. This reference provides the most comprehensive guide of how to treat patients with hypertension. CrossRef
- Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913. CrossRef
- Farnett L, Mulrow CD, Linn WD, et al.: The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991, 265:489–495. CrossRef
- Kaplan NM: Critical comments on recent literature. The J curve and other problems with therapy. Am J Hypertens 1989, 2:132–133.
- Messerli FH, Kupfer S, Pepine CJ: J curve in hypertension and coronary artery disease. Am J Cardiol 2005, 95:160. CrossRef
- Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762. CrossRef
- de ZD, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921–927. CrossRef
- Berl T, Hunsicker LG, Lewis JB, et al.: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005, 16:2170–2179. CrossRef
- Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016. CrossRef
- Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504. CrossRef
- LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425–1435. CrossRef
- Ford ES, Mokdad AH, Giles WH, Mensah GA: Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003, 107:2185–2189. CrossRef
- Russell LB, Valiyeva E, Carson JL: Effects of prehypertension on admissions and deaths: a simulation. Arch Intern Med 2004, 164:2119–2124. CrossRef
- Liszka HA, Mainous AG III, King DE, et al.: Prehypertension and cardiovascular morbidity. Ann Fam Med 2005, 3:294–299. CrossRef
- Kshirsagar AV, Carpenter M, Bang H, et al.: Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006, 119:133–141. CrossRef
- Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997, 157:657–667.
- The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. The Treatment of Mild Hypertension Research Group. Arch Intern Med 1991, 151:1413–1423.
- Julius S, Nesbitt SD, Egan BM, et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685–1697. CrossRef
- Elmer PJ, Obarzanek E, Vollmer WM, et al.: Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006, 144:485–495.
- Stevens VJ, Obarzanek E, Cook NR, et al.: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001, 134:1–11.
- Schiffrin EL, Deng LY, Larochelle P: Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients. J Cardiovasc Pharmacol 1994, 24(Suppl3):S51-S56.
- Rudnichi A, Safar M, Asmar R, et al.: Prevalence of cardiovascular risk factors in a French population. J Hypertens Suppl 1998, 16:S85-S90. CrossRef
- Deckert T, Kofoed-Enevoldsen A, Norgaard K, et al.: Microalbuminuria. Implications for micro-and macrovascular disease. Diabetes Care 1992, 15:1181–1191. CrossRef
- Gosling P: Microalbuminuria: a marker of systemic disease. Br J Hosp Med 1995, 54:285–290.
- Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW: Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997, 34:55–68. CrossRef
- O’Meara JG, Kardia SL, Armon JJ, et al.: Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004, 164:1313–1318. CrossRef
- Wilson PW, Kannel WB, Silbershatz H, D’Agostino RB: Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999, 159:1104–1109. CrossRef
- McLaughlin T, Abbasi F, Lamendola C, et al.: Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Metab 2000, 85:3085–3088. CrossRef
- Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304. CrossRef
- Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752. CrossRef
- Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006, 47:1093–1100. CrossRef
- Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.
- Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689. CrossRef
- De BG, Ambrosioni E, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003, 24:1601–1610. CrossRef
- Johnson ML, Pietz K, Battleman DS, Beyth RJ: Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care 2006, 44:39–46. CrossRef
- Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335–342. CrossRef
- Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427. CrossRef
- Weir MR, Rosenberger C, Fink JC: Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001, 14:963–968. CrossRef
- Andrews TC, Ballantyne CM, Hsia JA, Kramer JH: Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001, 111:185–191. CrossRef
- Karalis DG, Ross AM, Vacari RM, et al.: Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002, 89:667–671. CrossRef
- Thom T, Haase N, Rosamond W, et al.: Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151. CrossRef
- Expanding the definition of hypertension to incorporate global cardiovascular risk
Current Hypertension Reports
Volume 8, Issue 5 , pp 384-390
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors